Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Annovis Bio, Inc.NYSE: ANVS
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 702.9% from a year ago
Other current liabilities stood at $6.78M at the end of Q1 FY2026, up 702.9% from a year earlier and up 1401058.7% from the prior quarter. Over 3 fiscal years it compounded at +8796105.1% a year.
Context
- Other current liabilities amounted to 41.7% of total assets at the end of Q1 FY2026, up 38.6 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +702.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 618.66K USD
- Year-over-year change
- -48.9%
- 4-year CAGR
- +55.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 618.66K | -48.9% |
| FY2024 | 2024-12-31 | 1.21M | +443231.9% |
| FY2023 | 2023-12-31 | 273 | +30033003300230.0% |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 105.67K | — |
Other Current Liabilities vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 other current liabilities of $6.78M is the 2nd highest of the 6 companies compared; the peer median is $1.51M.
- Its year-over-year change of +702.9% is the highest of 4, against a peer median of +22.9%.
- Other current liabilities amounts to 41.7% of total assets for ANVS, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $6.93M | +331.5% | -20.6% | 6.5% | |
| Mar 2026 | $6.78M | +702.9% | +8796105.1% | 41.7% | |
| Mar 2026 | $3.55M | — | — | 18.5% | |
| Mar 2026 | $1.51M | +22.9% | +3.1% | 4.3% | |
| Mar 2026 | $453.63K | -29.1% | -47.1% | 1.8% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANVS) | $1.51M | +22.9% | -20.6% | 4.3% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.